公开(公告)号：EP1581309A2

公开(公告)日：2005-10-05

申请号：EP03812437.6

申请日：2003-11-14

申请人： Exelixis, Inc.

发明人： BANNEN, Lynne, Canne ,  BROWN, S., David ,  CHENG, Wei ,  CO, Erick, Wang ,  NUSS, John, M. ,  KIM, Moon, Hwan ,  KLEIN, Rhett Ronald ,  LE, Donna, T. ,  LEW, Amy ,  MAC, Morrison, B. ,  PARKS, Jason Jevious ,  WEN,, Zhaoyang ,  XU, Wei

IPC分类号： A61P35/00 ,  A61K31/445 ,  A61K31/44 ,  A61K31/52 ,  A61K31/415 ,  A61K31/535 ,  C07D235/00 ,  C07D401/00 ,  C07D413/00 ,  C07D471/00 ,  C07D487/00

CPC分类号： C07D403/14 ,  C07D401/14 ,  C07D413/14 ,  C07D451/04

摘要： The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides oxindole derivatives which inhibit, regulate and/or modulate kinase receptor, particularly VEGF receptor 2 (Flk-1/KDR), FGFR1, and PDGFR (alpha and beta), signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.